Spots Global Cancer Trial Database for Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
Official Title: Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
Study ID: NCT01187303
Conditions
Interventions
Study Description
Brief Summary: The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
1st Department of Medicine, Cologne University Hospital, Cologne, , Germany
Contact Details
Name: Andreas Engert, MD
Affiliation: University of Cologne
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
